Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
Cox K et al. |
Emerging Therapeutic Strategies in Breast Cancer. |
2017 |
South. Med. J. |
pmid:28973703
|
Diaby V et al. |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. |
2017 |
Breast Cancer Res. Treat. |
pmid:28840424
|
Sabbaghi M et al. |
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:28821558
|
Zhao M et al. |
Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. |
2017 |
Appl. Biochem. Biotechnol. |
pmid:27787765
|
van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Ait-Oudhia S et al. |
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. |
2017 |
AAPS J |
pmid:28646408
|
Loebrich S et al. |
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. |
2017 |
AAPS J |
pmid:28534292
|
Arvanitis CD et al. |
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. |
2018 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:30150398
|
Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Wang L et al. |
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. |
2018 |
Cancer Sci. |
pmid:30076657
|
Jin W et al. |
LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. |
2018 |
Bioanalysis |
pmid:29863890
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Johnson TA and Singla DK |
Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. |
2018 |
Can. J. Physiol. Pharmacol. |
pmid:29842793
|
Barok M et al. |
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
2018 |
BMC Cancer |
pmid:29720111
|
Sakai H et al. |
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
2018 |
Breast Cancer |
pmid:29700710
|
Zuradelli M et al. |
Never too old to fight breast cancer: A case report. |
2018 |
Medicine (Baltimore) |
pmid:29489698
|
Madden R et al. |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. |
2018 |
Int J Clin Pharmacol Ther |
pmid:29231164
|
Nittoli T et al. |
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. |
2018 |
Bioorg. Med. Chem. |
pmid:29605304
|